Zero Ischemia Laparoscopic Radio Frequency/Microwave Ablation Assisted Enucleation of Renal Cell Carcinoma With T1 Stage
- Conditions
- Kidney Neoplasms
- Interventions
- Procedure: conventional laparoscopic partial nephrectomyProcedure: zero ischemia laparoscopic RFA/MVA assisted tumor enucleation (TE)
- Registration Number
- NCT02734329
- Lead Sponsor
- RenJi Hospital
- Brief Summary
Zero ischemia laparoscopic radio frequency ablation assisted tumor enucleation has been proved to enable tumor excision with relatively better renal function preservation comparing with conventional laparoscopic partial nephrectomy for T1a renal cell carcinoma (RCC) in a randomized clinical trial in single center. The investigators want to explore this technique to T1 RCC patients in randomized clinical trial in multiple centers.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 600
- patients with sporadic, unilateral, newly diagnosed T1 presumed renal cell carcinoma
- patients scheduled for laparoscopic nephron sparing surgery
- patients agreeable to participate in this long-term follow-up study
- patients' aged >80 years
- patients with other renal diseases,(including kidney stone, glomerular nephritis, etc.) which might affect the renal function of the operative kidney
- patients not able to tolerate the laparoscopic procedure
- patients with previous renal surgery or history of any inflammatory conditions of the operative kidney
- patients with the renal tumor involving urinary collecting system
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Conventional group conventional laparoscopic partial nephrectomy Renal hilum will be accurately isolated and then the artery only will be clamped during surgery. Zero Ischemia group zero ischemia laparoscopic RFA/MVA assisted tumor enucleation (TE) Radiofrequency ablation(RFA) /Microwave ablation(MVA) will be performed for 1 to 4 cycles each depending on tumor size and depth. The tumor then will be laparoscopic enucleation without hilar clamping in most cases.
- Primary Outcome Measures
Name Time Method the change in glomerular filtration rate (GFR) of the affected kidney Baseline and 30 months changes of estimated GFR (eGFR) Baseline and 30 months
- Secondary Outcome Measures
Name Time Method estimated blood loss during surgery postoperative complications postoperative,up to 30 days progression-free survival rate through study completion, an average of 3 years rates of positive surgical margin postoperative,up to 2 weeks after surgery operative time During surgery the rate of local recurrence through study completion, an average of 3 years Hospital stay time The time from the surgery day to patient discharge, up to 2 weeks
Trial Locations
- Locations (1)
Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
🇨🇳Shanghai, China